Most Read Articles
01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
31 Oct 2017
In patients with underlying heart failure (HF) or chronic obstructive pulmonary disease (COPD), concurrent episodes of community-acquired pneumonia increase the risk of disease exacerbations, such as short-term cardiac complications and respiratory failure, a recent study has shown.
16 Mar 2017
Probiotics have a long history of use in humans. Defined as "live organisms that confer a health benefit on the host when administered in adequate amounts", the spectrum of use of probiotics in humans ranges from foods and dietary supplements to pharmaceutical/nutraceutical products to affect general health and disease. While the genera Lactobacillus and Bifidobacterium are the two most common probiotics associated with consumer products, there exist other organisms (eg, the yeast Saccharomyces cerevisiae, some non-pathogenic strains of Escherichia coli and Bacillus species) that are used as probiotics.1–3 One of them is the probiotic strain B. clausii that has been found to be effective for the treatment of diarrhoea and antibiotic-associated gastrointestinal side effects.4–6
02 Nov 2017
Passive immunization with neutralizing antibodies (nAbs) do not appear to prevent transmission of HIV-1 to the infant from the infected mother’s breastmilk, a recent study suggests.

Self-administered isoniazid, rifapentine noninferior to directly observed treatment of latent TB infection

10 Nov 2017

Self-administered, once-weekly isoniazid and rifapentine to treat latent tuberculosis infection is feasible in the United States, and this treatment can be used in similar settings when direct observation is not viable, suggests a new study.

A total of 1,002 adults (median age 36 years; 48 percent women; 77 percent enrolled at the US sites) from outpatient tuberculosis clinics in the US, Spain, Hong Kong and South Africa received once-weekly isoniazid and rifapentine by direct observation, self-administration with monthly monitoring, or self-administration with weekly text message reminders and monthly monitoring.

Treatment completion, defined as 11 or more doses within 16 weeks and measured using clinical documentation and pill counts for direct observation, and self-reports, pill counts and medication event-monitoring devices for self-administration, was the primary outcome. The secondary outcomes were adverse events.

Treatment completion was highest in the direct-observation group at 87.2 percent (95 percent CI, 83.1 to 90.5 percent), followed by 76.4 percent (71.3 to 80.8 percent) in the self-administration‒with‒reminders group and 74.0 percent (68.9 to 78.6 percent) in the self-administration group.

In the US, treatment completion was 85.4 (80.4 to 89.4), 76.7 (70.9 to 81.7 percent) and 77.9 (72.7 to 82.6 percent), respectively. Self-administered therapy without reminders was noninferior to direct observation in the US, and no other comparisons met the noninferiority criteria.

There were a few and similar drug-related adverse events across all groups.

“Expanding latent tuberculosis treatment is important to decrease active disease globally. Once-weekly isoniazid and rifapentine for 12 doses is effective but limited by requiring direct observation,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
31 Oct 2017
In patients with underlying heart failure (HF) or chronic obstructive pulmonary disease (COPD), concurrent episodes of community-acquired pneumonia increase the risk of disease exacerbations, such as short-term cardiac complications and respiratory failure, a recent study has shown.
16 Mar 2017
Probiotics have a long history of use in humans. Defined as "live organisms that confer a health benefit on the host when administered in adequate amounts", the spectrum of use of probiotics in humans ranges from foods and dietary supplements to pharmaceutical/nutraceutical products to affect general health and disease. While the genera Lactobacillus and Bifidobacterium are the two most common probiotics associated with consumer products, there exist other organisms (eg, the yeast Saccharomyces cerevisiae, some non-pathogenic strains of Escherichia coli and Bacillus species) that are used as probiotics.1–3 One of them is the probiotic strain B. clausii that has been found to be effective for the treatment of diarrhoea and antibiotic-associated gastrointestinal side effects.4–6
02 Nov 2017
Passive immunization with neutralizing antibodies (nAbs) do not appear to prevent transmission of HIV-1 to the infant from the infected mother’s breastmilk, a recent study suggests.